Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma

A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma